← Russell 3000 cross-section

SGRY Surgery Partners, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$1.8bn
Revenue TTM
$3.4bn
Net income TTM
$-89m
Free cash flow
$188m
Composite score
81.9
Sector rank
#1689

Valuation

P / E
EV / EBITDA
2.9
EV / sales
0.5
FCF yield
10.20%
Earnings yield vs 10-yr
-9.55pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-2.6%
EBITDA margin
16.7%
ROE
-5.3%
ROIC
26.4%
Revenue growth
4.0%

Insider activity, last 90 days

Net open-market
$0.14m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total revenues for the second quarter of 2026 increased 2.7% to $848.9 million from $826.2 million in the second quarter of 2025. The increase in revenues was attributable to same-facility revenue growth in 2026. Days adjusted same-facility revenues for the second quarter of 2026 increased 5.0% from the second quarter of 2025, with a 4.8% increase in revenue per case and a 0.3% increase in same-facility cases. For the second quarter of 2026, Adjusted EBITDA decreased 2.9% to $125.2 million compared to $129.0 million for the same period in 2025. …Surgery Partners, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →